Industry Spotlight

Medlab signs agreement for new study

7 March 2017 via Biotech Dispatch: Medical life science company, Medlab Clinical Limited (ASX:MDC), has signed an agreement to initiate a study to compare how its NanoCelle Atorvastatin oral spray, called ‘NanoStat’, patent pending, compares with taking statin tablets, like Lipitor, the off patent market leader.

The size of the statins market worldwide, predominantly comprised of tablets, is significant and has been estimated at US$12 billion in 2018.

Read more in Biotech Dispatch.